Profile data is unavailable for this security.
About the company
Pulse Biosciences, Inc. is a bioelectric medicine company. The Company’s proprietary CellFX nsPFA technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is engaged in the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. The Company’s Nano-pulse Stimulation (NPS) technology is an energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. The Company has designed a variety of applicators, or end-effectors, to explore the potential use of the CellFX platform to treat disorders in other medical specialties, such as cardiology, gastroenterology, gynecology, and ear, nose, and throat.
- Revenue in USD (TTM)0.00
- Net income in USD-42.21m
- Incorporated2018
- Employees56.00
- LocationPulse Biosciences Inc3957 Point Eden WayHAYWARD 94545-3720United StatesUSA
- Phone+1 (510) 906-4600
- Fax+1 (302) 655-5049
- Websitehttps://www.pulsebiosciences.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sight Sciences Inc | 81.06m | -55.55m | 288.40m | 214.00 | -- | 2.38 | -- | 3.56 | -1.14 | -1.14 | 1.67 | 2.45 | 0.4269 | 1.70 | 5.51 | 378,761.70 | -29.26 | -38.78 | -31.77 | -42.20 | 85.34 | 80.74 | -68.53 | -105.14 | 12.65 | -10.59 | 0.2201 | -- | 13.63 | 60.84 | 35.59 | -- | 6.77 | -- |
| AxoGen Inc | 159.01m | -21.72m | 291.07m | 426.00 | -- | 3.00 | -- | 1.83 | -0.5070 | -0.5070 | 3.71 | 2.22 | 0.8108 | 1.63 | 6.72 | 373,267.60 | -11.07 | -13.92 | -12.85 | -15.84 | 78.46 | 79.74 | -13.66 | -20.28 | 2.14 | -- | 0.3277 | -- | 14.74 | 13.63 | 24.98 | -- | 17.70 | -- |
| Pulmonx Corp | 68.68m | -60.84m | 291.09m | 279.00 | -- | 2.44 | -- | 4.24 | -1.60 | -1.60 | 1.81 | 3.07 | 0.3698 | 1.14 | 6.61 | 246,147.00 | -32.76 | -26.27 | -36.90 | -28.97 | 73.90 | 71.95 | -88.60 | -93.76 | 5.77 | -- | 0.2394 | -- | 27.98 | 27.98 | -3.26 | -- | 20.62 | -- |
| Bioventus Inc | 502.76m | -122.57m | 322.20m | 970.00 | -- | 1.81 | -- | 0.6409 | -1.97 | -2.93 | 8.06 | 2.25 | 0.4552 | 2.14 | 4.10 | 448,889.30 | -14.34 | -- | -18.91 | -- | 62.87 | 70.26 | -31.51 | -9.18 | 0.9443 | 0.3731 | 0.6354 | -- | 18.85 | 11.89 | -919.12 | -- | -- | -- |
| CVRx Inc | 39.30m | -41.20m | 329.98m | 200.00 | -- | 4.20 | -- | 8.40 | -1.99 | -1.99 | 1.89 | 3.64 | 0.3272 | 0.6974 | 6.02 | 196,475.00 | -34.31 | -- | -36.75 | -- | 84.08 | -- | -104.85 | -- | 12.86 | -23.96 | 0.2779 | -- | 74.89 | -- | 0.5528 | -- | -- | -- |
| Tactile Systems Technology Inc | 274.42m | 28.52m | 335.72m | 992.00 | 11.90 | 1.72 | 9.58 | 1.22 | 1.19 | 1.19 | 11.90 | 8.20 | 1.02 | 6.02 | 5.60 | 276,636.10 | 10.63 | 0.9015 | 13.23 | 1.09 | 49.95 | 49.10 | 10.39 | 0.8309 | 2.99 | -- | 0.1308 | 0.00 | 11.20 | 13.81 | 259.60 | 33.91 | -23.62 | -- |
| Zynex Inc | 184.32m | 9.73m | 365.59m | 1.10k | 42.77 | 8.30 | 26.20 | 1.98 | 0.2677 | 0.2677 | 5.10 | 1.38 | 1.45 | 2.86 | 5.96 | 167,565.50 | 7.68 | 14.58 | 9.11 | 17.52 | 79.38 | 79.62 | 5.28 | 10.44 | 4.03 | 9.85 | 0.5581 | -- | 16.54 | 42.01 | -42.91 | 0.3741 | 2.19 | -- |
| Surmodics Inc | 138.20m | 5.52m | 368.00m | 376.00 | 66.10 | 3.01 | 25.82 | 2.66 | 0.3911 | 0.3911 | 9.82 | 8.58 | 0.7897 | 2.10 | 7.05 | 367,561.20 | 3.15 | -1.85 | 3.49 | -2.18 | 79.38 | 82.93 | 3.99 | -2.98 | 3.97 | 5.84 | 0.1942 | -- | 32.65 | 10.27 | 94.37 | -- | -27.02 | -- |
| MaxCyte Inc | 41.29m | -37.92m | 382.09m | 143.00 | -- | 1.64 | -- | 9.25 | -0.3675 | -0.3675 | 0.3998 | 2.23 | 0.1488 | 0.4558 | 4.27 | 288,727.30 | -13.67 | -13.18 | -14.54 | -14.33 | 88.51 | 88.79 | -91.85 | -62.96 | 9.97 | -- | 0.00 | -- | -6.72 | 19.89 | -60.89 | -- | 39.13 | -- |
| Neuropace Inc | 65.42m | -32.96m | 388.58m | 171.00 | -- | 18.23 | -- | 5.94 | -1.28 | -1.28 | 2.53 | 0.7423 | 0.590 | 1.65 | 6.61 | 382,578.90 | -29.72 | -- | -33.88 | -- | 73.56 | -- | -50.38 | -- | 5.02 | -4.97 | 0.7339 | -- | 43.72 | -- | 30.00 | -- | -- | -- |
| Pulse Biosciences Inc | 0.00 | -42.21m | 400.38m | 56.00 | -- | 9.01 | -- | -- | -0.8936 | -0.8936 | 0.00 | 0.8044 | 0.00 | -- | -- | 0.00 | -61.61 | -93.21 | -67.89 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| Nevro Corp | 425.17m | -92.21m | 418.90m | 1.22k | -- | 1.42 | -- | 0.9853 | -2.57 | -2.57 | 11.82 | 8.06 | 0.6868 | 1.24 | 5.37 | 349,937.40 | -14.90 | -13.64 | -17.15 | -16.68 | 68.22 | 68.54 | -21.69 | -20.67 | 4.94 | -- | 0.4191 | -- | 4.63 | 1.88 | -3,172.74 | -- | 0.9012 | -- |
| ZimVie Inc | 457.43m | -56.05m | 426.55m | 2.60k | -- | 1.04 | -- | 0.9325 | -2.12 | -14.87 | 17.33 | 15.12 | 0.3213 | 1.07 | 3.91 | 175,935.80 | -3.94 | -- | -4.56 | -- | 63.48 | 65.51 | -12.25 | -8.73 | 2.32 | -0.5562 | 0.5541 | -- | -1.26 | -16.08 | -19.50 | -- | -23.70 | -- |
| Pacific Biosciences of California Inc | 200.52m | -306.74m | 428.72m | 796.00 | -- | 0.6109 | -- | 2.14 | -1.21 | -1.21 | 0.7907 | 2.62 | 0.1142 | 2.70 | 7.24 | 251,910.80 | -17.46 | -16.19 | -19.45 | -17.81 | 28.03 | 37.35 | -152.97 | -136.21 | 7.21 | -22.45 | 0.5601 | -- | 56.29 | 20.59 | 2.39 | -- | 36.68 | -- |
| Orthofix Medical Inc | 746.64m | -151.40m | 489.65m | 1.63k | -- | 0.8125 | -- | 0.6558 | -4.15 | -4.15 | 20.33 | 16.11 | 1.08 | 1.62 | 7.08 | 456,940.60 | -21.88 | -8.88 | -26.68 | -10.96 | 65.13 | 72.37 | -20.28 | -9.28 | 1.20 | -16.11 | 0.1595 | -- | 62.06 | 10.51 | -666.60 | -- | 30.01 | -- |
| Iradimed Corp | 65.56m | 17.19m | 517.91m | 148.00 | 30.28 | 7.25 | 28.84 | 7.90 | 1.35 | 1.35 | 5.15 | 5.64 | 0.738 | 1.69 | 5.14 | 442,988.50 | 19.35 | 13.16 | 22.51 | 14.58 | 76.50 | 76.55 | 26.22 | 21.46 | 3.87 | -- | 0.00 | 68.13 | 23.00 | 16.59 | 34.02 | 22.22 | 97.77 | -- |
Data as of Apr 30 2024. Currency figures normalised to Pulse Biosciences Inc's reporting currency: US Dollar USD
6.80%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 984.21k | 1.79% |
| Bank of America, NA (Private Banking)as of 31 Dec 2023 | 784.20k | 1.43% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 638.20k | 1.16% |
| Geode Capital Management LLCas of 31 Dec 2023 | 379.26k | 0.69% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 309.52k | 0.56% |
| Griffin Asset Management, Inc.as of 31 Mar 2024 | 300.32k | 0.55% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2023 | 183.67k | 0.33% |
| Spotlight Asset Group, Inc.as of 31 Dec 2023 | 72.09k | 0.13% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2023 | 43.70k | 0.08% |
| BlackRock Investment Management LLCas of 31 Dec 2023 | 43.64k | 0.08% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
